<DOC>
	<DOC>NCT00904280</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and tolerability of oxymorphone ER as an analgesic in cancer and lower back pain subjects having chronic moderate to severe pain.</brief_summary>
	<brief_title>Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>The subject enrolled in this study must have been previously randomized and dosed in the doubleblind treatment period of study EN3202016 or EN3202019 and completed the exit visits for these studies. Males or females, age 18 and 75 years, inclusively. The subject continues to have chronic moderate to severe back or cancer pain that requires opioid medication. Women must continue to be of nonchildbearing potential. The subject experienced any serious drug related adverse events in studies EN3202016 or EN3202019. The subject withdrew from EN3202016 or EN3202019 for a reason other than lack of efficacy. Subjects with known allergies to opiateclass narcotic agents (morphine, codeine, hydrocodone, propoxyphene, meperidine, oxycodone, etc.) or naproxen, or subjects who have any medical condition in which opiates are medically contraindicated.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>